The indication for The Medicines Co.’s antiplatelet drug Kengreal may suggest FDA agreed with advisory committee members’ opinions that the product will only serve a small population.
The agency announced June 22 that it had approved Kengreal (cangrelor) for injection as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of myocardial infarction, repeat coronary revascularization and stent thrombosis, but only in patients that had not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI), according to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?